聶明明

[關(guān)鍵詞] 達格列凈;德谷胰島素;糖尿病;生活質(zhì)量

[中圖分類號] R587.1? ? ? ? ? [文獻標(biāo)識碼] A? ? ? ? ? [文章編號] 1673-9701（2021）25-0013-04

Effect of dapagliflozin combined with insulin degludec in treatment of diabetes

NIE Mingming

Department of Endocrinology， Jiamusi Central Hospital in Heilongjiang Province， Jiamusi? ?154002， China

[Abstract] Objective To explore the effect of dapagliflozin combined with insulin degludec in the treatment of diabetes. Methods A total of 72 patients with type 2 diabetes admitted to our hospital from January 2018 to December 2019 were randomly divided into two groups， with 36 patients in each group. Both groups were given subcutaneous insulin degludec injection at any time each day.Additionally， the observation group were given combined oral dapagliflozin tablets in the morning. The efficacy， blood glucose index， body weight， HOMA-IR， fasting C-peptide and HOMA-β were compared between the two groups， and the quality of life was evaluated. Results After treatment， the total effective rate of the observation group was significantly higher than that of the control group（P<0.05）.The FBG， HbA1c， 2 hPG and body weight of the observation group were （7.25±0.82）mmol/L， （7.15±0.63）%， （8.87±1.14）mmol/L and （58.72±10.41） kg， which were significantly lower than those of the control group as （8.15±1.13）mmol/L， （7.90±0.84）%， （10.29±1.35）mmol/L and （63.34±10.64）kg， with statistically significant differences（P<0.05）. The HOMA-IR， fasting C-peptide and HOMA-β of the observation group were （5.63±1.34）， （0.77±0.08）ng/mL and （3.17±0.42）， and those of the control group were （4.25±1.27）， （0.43±0.07）ng/mL and （6.13±0.64）， with statistically significant differences（P<0.05）.The scores of physiological dimension， disease severity， social dimension， satisfaction， psychological dimension and DMQLS of the observation group were （45.29±1.14）points， （45.62±2.45）points， （45.15±3.24）points， （46.27±2.33）points， （45.29±2.63） points and （229.35±3.31）points， and those of the control group were （49.38±10.95）points， （48.73±2.45） points， （48.16±2.45）points， （49.01±1.36）points， （49.36±2.43）points and （250.45±11.68）points with statistically significant differences（P<0.05）. Conclusion Dapagliflozin combined with insulin degludec can effectively control the blood sugar of patients with diabetes.It is worthy of promotion.

[Key words] Dapagliflozin; Insulin degludec; Diabetes; Quality of life